Immunome (NasdaqCM:IMNM) FY Conference Transcript

Summary of Immunome Conference Call Company Overview - Company: Immunome - Focus: Targeted oncology with a pipeline of differentiated products, including first-in-class and best-in-class therapies [2][3] Key Product: Varegacestat - Description: An oral gamma secretase inhibitor for treating desmoid tumors, with a once-daily dosing regimen [3][4] - Clinical Data: - Phase 3 RINGSIDE study showed: - 84% reduction in risk of progression (hazard ratio of 0.16) - 56% objective response rate - 83% median best tumor volume reduction [3][6] - NDA Submission: Planned for Q2 2026, with no anticipated roadblocks [4][10] - Market Potential: - Estimated 10,000-11,000 patients in the U.S. with desmoid tumors, with only 10% currently on gamma secretase inhibitors [9][22] - Potential to capture a significant share of the market, with a target of 3,000 patients translating to a billion-dollar annual revenue [22] Competitive Landscape - Nirogacestat: The only approved systemic therapy for desmoid tumors, approved in late 2023. Varegacestat offers a better pharmacokinetic profile and once-daily dosing compared to Nirogacestat [5][9] - Market Dynamics: - OGSIVEO's launch has faced challenges, potentially limiting market growth. Immunome aims to differentiate by emphasizing the benefits of varegacestat [22][23] ADC Portfolio - Technology: Immunome is developing a proprietary ADC payload (HC74) to overcome limitations of existing ADCs, such as therapeutic window and resistance pathways [10][13] - Current ADCs: - IM-1021: ROR1-targeted ADC in dose escalation, focusing on lymphoma [11][12] - Upcoming ADCs: Three additional ADCs expected to enter clinical trials in 2026, all utilizing HC74 technology [16][17] - Market Strategy: Emphasis on selecting appropriate targets and optimizing ADC design to enhance efficacy and reduce toxicity [34][35] Radiotherapy Program - IM-3050: FAP-targeted radiotherapy with an active IND, expected to dose the first patient soon [17][48] - Market Opportunity: FAP is expressed in 75% of solid tumors, presenting a significant potential market [48] Financial and Commercial Strategy - Cost-effective Launch: Plans for a lean commercial infrastructure with approximately 32-35 sales reps, focusing on maximizing patient benefit and adherence [28][29] - Long-term Vision: Immunome aims to build a comprehensive portfolio of breakthrough oncology therapies, with varegacestat as the first clinical success [17][49] Conclusion - Investment Outlook: Immunome is currently valued primarily on varegacestat, with significant potential for the ADC portfolio to contribute to future growth [49]